Pembrolizumab-Associated Cutaneous and Pulmonary Sarcoidosis in Non-Small Cell Lung Cancer Treatment. 

 -  2022 
<br/><br/> Immune checkpoint inhibitor (ICI) therapy has reshaped the treatment landscape in many cancers including non-small cell lung cancer (NSCLC). ICI-therapy can lead to a diverse array of immune-related adverse effects (irAEs), and prompt recognition and management are key to successful treatment. With wide-spread use of ICI therapy in clinical practice, rare irAEs are being increasingly recognized. This report documents a patient with advanced NSCLC who developed pembrolizumab-associated sarcoidosis with multiorgan involvement. Multidisciplinary management led to timely diagnosis and treatment, leading to improvement in symptoms. This case raises awareness of sarcoidosis as a rare side effect of pembrolizumab. Copyright © 2022. Published by Elsevier Inc. 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>1525-7304 
<br/><br/><label>Standard No.: </label>10.1016/j.cllc.2022.05.011 [doi] S1525-7304(22)00107-3 [pii] 
<br/><br/><label>Subjects--Topical Terms: </label><br/>*Carcinoma, Non-Small-Cell Lung<br/>*Drug-Related Side Effects and Adverse Reactions<br/>*Lung Neoplasms<br/>*Sarcoidosis<br/>*Sarcoidosis, Pulmonary<br/>Antibodies, Monoclonal, Humanized<br/>Carcinoma, Non-Small-Cell Lung/dt [Drug Therapy]<br/>Humans<br/>Lung Neoplasms/di [Diagnosis]<br/>Sarcoidosis, Pulmonary/ci [Chemically Induced]<br/>Sarcoidosis, Pulmonary/di [Diagnosis]<br/>Sarcoidosis/ci [Chemically Induced]<br/>Sarcoidosis/di [Diagnosis]
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Washington Hospital Center
<br/><br/><label>Index Terms--Occupation: </label><br/>Dermatology
<br/><br/><label>Index Terms--Function: </label><br/>Case Reports